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Abstract
This study determined whether, and by how much, the cost-effectiveness of contingency
management (CM) varied across the eight clinics in the National Institute on Drug Abuse Clinical
Trials Network MIEDAR trial. Incremental costs, incremental outcomes, and incremental cost-
effectiveness ratios (ICERs) of CM compared to usual care were calculated, compared and
contrasted for each of the clinics. Results showed that the incremental cost of using CM compared
to usual care varied by a factor of 1.9 across the clinics, ranging from an additional $306 to an
additional $582 per patient. The effect of CM on the longest duration of continuous stimulant
abstinence (LDA) varied by a factor of 8.0 across the clinics, ranging from an additional 0.5 to an
additional 4.0 weeks. The ICERs for the LDA varied by a factor of 4.6 across the clinics, ranging
from $145 to $666. These results show that the cost-effectiveness of CM varied widely among the
clinics in the MIEDAR trial. Future research should focus on identifying the sources of this
variation, perhaps by identifying clinic-level best practices and/or identifying those subgroups of
patients that respond the most cost-effectively, with the ultimate goal of improving the cost-
effectiveness of CM overall.
INTRODUCTION
Contingency management (CM) interventions are based on behavioral research
demonstrating that when a behavior is reinforced, it increases in frequency. In the substance
abuse treatment field, CM interventions typically provide substance abusers with tangible
incentives (e.g., chances to win prizes exchangeable for retail goods and services),
contingent upon submission of urine specimens that test negative for recent drug use. Many
studies have shown that CM interventions are effective tools for improving treatment
outcomes across a wide range of substance-abusing populations and treatment modalities.1–
8
Despite the strong evidence base for CM interventions, these tools have not been adopted
widely in the United States or elsewhere.9 One major hindrance to wider adoption of CM
interventions is that not much is known about their cost-effectiveness.10,11 At issue is
whether the additional expense associated with CM is cost-effective in terms of the
additional value gained. To shed light on this issue, Olmstead, Sindelar, and Petry12 recently
examined the cost-effectiveness of using CM to treat stimulant abusers. This multi-site cost-
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effectiveness study was based on a randomized clinical trial conducted within the National
Institute on Drug Abuse Clinical Trials Network (CTN).1 The underlying trial, called
MIEDAR (Motivational Incentives for Enhanced Drug Abuse Recovery), took place in eight
community-based outpatient psychosocial (i.e., drug-free) clinics with a diverse set of
clienteles, usual care practices, and geographic locations. The purpose of the Olmstead,
Sindelar, and Petry study was to estimate the average cost-effectiveness of CM compared to
usual care, where the average was taken across all of the trial participants. Therefore, data
(i.e., costs and patient outcomes) from the eight clinics were pooled, and the study reported
only the overall (or aggregate) cost-effectiveness of CM compared to usual care. Given the
diversity of clinics included in MIEDAR, the aggregate incremental cost-effectiveness
ratios (ICERs) presented in the Olmstead, Sindelar, and Petry study provide useful estimates
of the population-average incremental cost-effectiveness of CM. Said differently, the
aggregate ICERs in the Olmstead, Sindelar, and Petry study should be useful to policy
makers interested in predicting the average cost-effectiveness of CM were it to be
implemented widely across the United States.
Although overall (or aggregate) cost-effectiveness results are useful for high-level decision
making (perhaps related to the future expansion of CM), they do not provide insight into the
potential heterogeneity in cost-effectiveness among clinics in multi-site trials. Thus,
important questions remaining from the Olmstead, Sindelar, and Petry study are whether,
and by how much, the cost-effectiveness of CM varies across clinics? If clinics are
heterogeneous with respect to the cost-effectiveness of CM, then further research is
warranted to identify the sources of such variation with the goal of developing more cost-
effective methods of implementing CM in practice. For example, case studies may be able to
identify ‘‘best practices’’ at those clinics where CM is relatively more cost-effective, and
these ‘‘best practices’’ could then be shared with those clinics where CM is relatively less
cost-effective, thereby improving the cost-effectiveness of CM overall.
This study extends our previous work by examining whether, and by how much, the cost-
effectiveness of CM varies across the clinics in the MIEDAR trial. Specifically, for each of
the eight clinics in the MIEDAR trial, we calculate, compare and contrast the incremental
costs, incremental outcomes, and incremental cost-effectiveness ratios (ICERs) of CM
compared to usual care. We also present acceptability curves to further illustrate the
heterogeneity in the cost-effectiveness of CM among the clinics. Our study adds to the small
but growing literature on the cost-effectiveness of CM12,13 and to the literature on the cost-
effectiveness of treatment for substance abuse in general.14–19
METHODS
Methods and results of the MIEDAR effectiveness trial and overall cost-effectiveness study
are described in detail in earlier publications,1,12 and summarized briefly below. Then we
describe our clinic-specific analytical methods.
MIEDAR Effectiveness Trial1
The MIEDAR trial evaluated the effectiveness of prize-based CM as compared to usual care
in each of eight outpatient psychosocial community-based substance abuse treatment clinics
that were members of the CTN. The study intervention lasted for 12 weeks, and the final
study sample comprised 415 stimulant-abusing participants who were randomly assigned to
either usual care (UC) or usual care plus prize-based incentives. UC consisted primarily of
group and possibly some individual and family counseling, depending on the clinic.
Participants assigned to the prize-based CM condition, in addition to receiving usual care,
earned the chance to win prizes for submitting substance-negative urine samples. Those who
submitted substance-negative samples were invited to draw between one and 12 square
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plastic chips from an opaque container containing 500 chips. Half of the chips were marked
‘‘Good Job’’ and had no monetary value; the other half of the chips were exchangeable for
goods ranging in value from $1 to $100. The number of draws earned increased with
duration of continuous abstinence, but was reset to one draw after an unexcused absence or a
positive sample. The escalating reward system was designed to reinforce long durations of
abstinence.
Overall (Pooled) Cost-Effectiveness Study12
The Olmstead, Sindelar, and Petry overall cost-effectiveness study conducted an incremental
cost-effectiveness analysis20,21 to answer the question of value per dollar spent on prize-
based CM over usual care. All analyses used data that were pooled across the eight clinics in
the study. Cost data were collected via surveys administered to each of the clinics, while
data on resources used and patient outcomes were obtained from the MIEDAR trial.
Incremental cost-effectiveness ratios (ICERs) were then calculated from the pooled data for
each of the three patient outcomes in the study: longest duration of abstinence (LDA) from
primary target drugs, length of stay in the study, and number of stimulant-negative urine
samples submitted. The ICERs measure the incremental cost of using CM, compared to
usual care, to produce an additional unit of effect for each of the patient outcomes. In
addition, an acceptability curve for the primary patient outcome LDA was presented to
illustrate the statistical uncertainty in the ICERs due to the study sample and to provide
policy relevant information.22,23
Clinic-Specific Cost-Effectiveness Analysis
Following the methods described in Olmstead, Sindelar, and Petry,12 we first calculate the
incremental costs, incremental outcomes, and ICERs for each of the three patient outcomes
at each of the eight clinics in the study. We then use the following two straightforward
measures to assess the degree of heterogeneity in the incremental costs, incremental
outcomes, and ICERs among the clinics: the difference between the highest and lowest
observations (i.e., the range) and the ratio of the highest and lowest observations. We also
present acceptability curves for the primary patient outcome LDA to further illustrate the
heterogeneity in the cost-effectiveness of CM among the clinics.
RESULTS
Table 1 shows the incremental costs, incremental outcomes, and ICERs of CM compared to
usual care (UC) at each of the clinics in the study, as well as the associated ranges and ratios
of the highest and lowest observations in each category. Clearly, there is substantial
variation across the clinics in every category. For example, the incremental cost of using
CM compared to UC varies by a factor of 1.9 across the clinics, ranging from an additional
$306 per patient at clinic #8 to an additional $582 per patient at clinic #2. The effect of CM
on patient outcomes varies even more. The effect of CM on the LDA, for example, varies by
a factor of 8.0 across the clinics, ranging from an additional 0.5 weeks at clinic # 5 to an
additional 4.0 weeks at clinic #1.
Given the substantial variation across clinics in both incremental costs and incremental
outcomes, it is not surprising that the ICERs vary considerably as well. The ICERs for the
patient outcome LDA, for example, vary by a factor of 4.6 across the clinics, ranging from
$145 at clinic #1 to $666 at clinic #5. Said differently, compared to UC, the incremental cost
of using prize-based CM to extend the LDA by one week is, on average, 4.6 times more
expensive at clinic #5 than it is at clinic #1.
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To further illustrate the heterogeneity in the cost-effectiveness of CM among the clinics,
Figure 1 shows acceptability curves for the patient outcome LDA at each of the clinics. Each
acceptability curve in Figure 1 shows the probability that CM would be considered cost-
effective at a given clinic for a large set of alternative values that decision makers could
place on extending the LDA by one week. As Figure 1 shows, for a wide range of possible
threshold values, there is substantial variation among the clinics with respect to the
probabilities that CM would be considered cost-effective. For example, if the threshold
value (perhaps determined by society’s willingness to pay) to extend the LDA by one week
were $250, then the probability that CM would be considered cost-effective ranges from
10% at clinic #5 to 50% at clinics #2 and #4 to 98% at clinic #1.
DISCUSSION
This study found strong evidence of heterogeneity in the cost-effectiveness of CM among
the eight clinics in the MIEDAR trial. Specifically, substantial variation among the clinics
was found in the incremental costs, incremental outcomes, and incremental cost-
effectiveness ratios of CM compared to usual care. Heterogeneity was also readily apparent
among the acceptability curves associated with the clinics.
These findings suggest that it may be possible to improve the cost-effectiveness of CM
overall. The next step is to understand the sources of the clinic variation in the cost-
effectiveness of CM. Is the variation due to specific clinic practices, client characteristics,
the interaction between clinic and clients, or to something else? The answers to these
questions have important implications for both how CM should be implemented and who
should receive it. For example, if the variation is due to clinic practices, then case studies
may be able to identify both ‘‘best practices’’ at those clinics where CM is relatively more
cost effective and barriers to implementing ‘‘best practices’’ at those clinics where CM is
relatively less cost effective. In addition, if the variation is due to client characteristics, then
it may be possible to target CM at those clients that are likely to be the most cost-effective to
treat with this intervention.
In conclusion, we find that the cost-effectiveness of CM varied widely among the clinics in
the MIEDAR trial. Unfortunately, because the MIEDAR trial did not collect detailed data on
clinic practices and case studies are beyond the scope of this paper, we are unable to identify
the sources of this clinic variation in the cost-effectiveness of CM. Nevertheless, our
findings demonstrate the need for future research that focuses on understanding the reasons
why CM is more cost-effective at some clinics than at others. By identifying clinic-level
‘‘best practices’’ and/or identifying those subgroups of patients that respond the most cost-
effectively to CM, it may be possible to improve the cost-effectiveness of CM overall.
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Figure 1.
Acceptability Curves for Longest Duration Abstinent (LDA) by Clinic
Olmstead et al. Page 6
Am J Addict. Author manuscript; available in PMC 2011 April 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Olmstead et al. Page 7
TA
B
LE
 1
In
cr
em
en
ta
l c
os
ts
, i
nc
re
m
en
ta
l o
ut
co
m
es
, a
nd
 IC
ER
s b
y 
cl
in
ic
*
In
cr
em
en
ta
l C
os
ts
 (C
M
–U
C
)
In
cr
em
en
ta
l O
ut
co
m
es
 (C
M
–U
C
)
IC
E
R
s
N
$
L
D
A
 (w
ee
ks
)
N
eg
 u
ri
ne
s
L
O
S 
(w
ee
ks
)
$/
w
ee
k 
of
 L
D
A
$/
ne
g 
ur
in
e
$/
w
ee
k 
of
 L
O
S
O
ve
ra
ll
41
2
43
8†
1.
7†
3.
0†
1.
1†
25
8
14
6
39
8
C
lin
ic
 1
67
58
1†
4.
0†
6.
0†
2.
3†
14
5
97
25
3
C
lin
ic
 2
48
58
2†
2.
4
3.
8
0.
9
24
3
15
3
64
7
C
lin
ic
 3
24
45
1†
2.
5
6.
7†
4.
2†
18
0
67
10
7
C
lin
ic
 4
32
53
5†
2.
1
5.
7†
2.
3
25
5
94
23
3
C
lin
ic
 5
55
33
3
0.
5
1.
6
1.
6
66
6
20
8
20
8
C
lin
ic
 6
88
41
1†
1.
1
2.
7
0.
5
37
4
15
2
82
2
C
lin
ic
 7
59
36
8†
0.
8
1.
3
0.
5
46
0
28
3
73
6
C
lin
ic
 8
39
30
6†
2.
0
1.
2
− 
0.2
15
3
25
5
− 
15
30
M
ax
/M
in
1.
9
8.
0
5.
6
n/
a
4.
6
4.
2
n/
a
M
ax
–M
in
27
6
3.
5
5.
5
4.
4
52
1
21
6
23
52
* T
hr
ee
 o
f t
he
 4
15
 p
ar
tic
ip
an
ts
 in
 th
e 
M
IE
D
A
R
 st
ud
y 
w
er
e 
ex
cl
ud
ed
 fr
om
 th
e 
pr
es
en
t s
tu
dy
 d
ue
 to
 m
is
si
ng
 d
at
a;
 a
ll 
th
re
e 
oc
cu
rr
ed
 a
t c
lin
ic
 #
3.
† p
 v
al
ue
 <
.0
5.
A
bb
re
vi
at
io
ns
: I
C
ER
 =
 in
cr
em
en
ta
l c
os
t-e
ff
ec
tiv
en
es
s r
at
io
; C
M
 =
 p
riz
e-
ba
se
d 
co
nt
in
ge
nc
y 
m
an
ag
em
en
t; 
U
C
 =
 u
su
al
 c
ar
e;
 L
D
A
 =
 lo
ng
es
t d
ur
at
io
n 
ab
st
in
en
t d
ur
in
g 
st
ud
y 
(w
ee
ks
); 
N
eg
 u
rin
es
 =
 n
um
be
r o
f
st
im
ul
an
t-n
eg
at
iv
e 
ur
in
es
 su
bm
itt
ed
 d
ur
in
g 
st
ud
y;
 L
O
S 
= 
le
ng
th
 o
f s
ta
y 
in
 st
ud
y 
(w
ee
ks
).
Am J Addict. Author manuscript; available in PMC 2011 April 7.
